secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001171843-25-004094
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB
--------------------------------------------------------------------------------

- Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.
- Arbutus now holds global rights to imdusiran; reports 8 patients achieved functional cure in Phase 2a trials IM-PROVE I/II to date.
- New Scientific Advisory Board formed with five HBV experts to advise on late-stage clinical development of cHBV pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/0001171843-25-004094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/f8k_062525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer